Medtronic (NYSE:MDT) Rating Increased to Buy at Wall Street Zen

Medtronic (NYSE:MDT) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Friday.

MDT has been the topic of several other reports. UBS Group raised their price objective on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research report on Wednesday, November 19th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. upped their price objective on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Citigroup lifted their target price on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Finally, Robert W. Baird set a $103.00 price target on Medtronic in a research note on Tuesday, December 16th. Fourteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Stock Performance

NYSE:MDT traded down $0.36 during mid-day trading on Friday, hitting $100.98. 8,482,130 shares of the company traded hands, compared to its average volume of 6,335,744. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock’s fifty day moving average price is $99.44 and its 200-day moving average price is $95.23. The firm has a market cap of $129.45 billion, a price-to-earnings ratio of 27.22, a price-to-earnings-growth ratio of 2.67 and a beta of 0.71. Medtronic has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the previous year, the company posted $1.26 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic will post 5.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medtronic

Several large investors have recently added to or reduced their stakes in the stock. Curbstone Financial Management Corp lifted its stake in shares of Medtronic by 1.8% in the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock valued at $537,000 after purchasing an additional 100 shares during the last quarter. Baker Tilly Wealth Management LLC raised its holdings in Medtronic by 3.3% during the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after buying an additional 102 shares during the period. Riverbend Wealth Management LLC lifted its position in Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock worth $332,000 after buying an additional 107 shares during the last quarter. Maseco LLP lifted its position in Medtronic by 32.1% in the fourth quarter. Maseco LLP now owns 444 shares of the medical technology company’s stock worth $43,000 after buying an additional 108 shares during the last quarter. Finally, Holistic Financial Partners boosted its stake in Medtronic by 3.0% during the third quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock worth $352,000 after buying an additional 109 shares during the period. 82.06% of the stock is owned by institutional investors.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).